Genesis achieved its sub-one-angstrom accuracy not through one algorithmic trick, but by making it a core objective from the start. This obsessive focus on the right metric guided countless small, compounding decisions across data, infrastructure, and modeling.

While AI models are effective for developability properties like stability, they fall short on predicting function. Sanofi's Norbert Furtman notes that generalized affinity prediction is a 'holy grail' problem, and predicting interference with a biological pathway is even harder, as function is not solely explained by structure.

To demonstrate industrial-scale viability, Chai Discovery tested its antibody design model on 50 different targets. This focus on generalization, far beyond the typical 2-4 targets shown in academic research, is crucial for proving a model is not a statistical anomaly and is ready for real-world application.

Similar to how an LLM uses a 'chain of thought' to reason, Genesis's model 'thinks' by iteratively refining an in-memory representation of a crystal structure. This process is guided by physics-based principles, significantly improving the final prediction's accuracy.

The community standard of two-angstrom accuracy for protein-ligand predictions is insufficient. At that resolution, critical details like an aromatic ring's orientation can be wrong, rendering the model's output misleading for drug design. Genesis argues one-angstrom accuracy is the minimum for practical utility.

The most significant gap in AI research is its focus on academic evaluations instead of tasks customers value, like medical diagnosis or legal drafting. The solution is using real-world experts to define benchmarks that measure performance on economically relevant work.

AI cannot yet revolutionize drug discovery because its strength is synthesizing existing knowledge. The problem is that humans only understand about 20% of the human body's biology, meaning the foundational dataset is too incomplete for AI to reliably predict outcomes for the unknown 80%.

Despite testing millions of compounds, high-throughput screening methods suffer from enormous false-positive rates. The actual predictive value for a re-synthesized molecule is extremely low, creating an opening for high-fidelity AI models to provide cleaner, more reliable predictions.

The bottleneck for AI in drug development isn't the sophistication of the models but the absence of large-scale, high-quality biological data sets. Without comprehensive data on how drugs interact within complex human systems, even the best AI models cannot make accurate predictions.